220 related articles for article (PubMed ID: 10755723)
21. Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients.
Salloum E; Brandt DS; Caride VJ; Cornelius E; Zelterman D; Schubert W; Mannino T; Cooper DL
J Clin Oncol; 1997 Feb; 15(2):518-27. PubMed ID: 9053473
[TBL] [Abstract][Full Text] [Related]
22. Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease.
Devizzi L; Maffioli L; Bonfante V; Viviani S; Balzarini L; Gasparini M; Valagussa P; Bombardieri E; Santoro A; Bonadonna G
Ann Oncol; 1997; 8 Suppl 1():53-6. PubMed ID: 9187430
[TBL] [Abstract][Full Text] [Related]
23. 18F-FDG PET is superior to 67Ga SPECT in the staging of non-Hodgkin's lymphoma.
Yamamoto F; Tsukamoto E; Nakada K; Takei T; Zhao S; Asaka M; Tamaki N
Ann Nucl Med; 2004 Sep; 18(6):519-26. PubMed ID: 15515753
[TBL] [Abstract][Full Text] [Related]
24. Utility of gallium-67 scintigraphy in low-grade non-Hodgkin's lymphoma.
Ben-Haim S; Bar-Shalom R; Israel O; Haim N; Epelbaum R; Ben-Shachar M; Gaitini D; Kolodny GM; Front D
J Clin Oncol; 1996 Jun; 14(6):1936-42. PubMed ID: 8656263
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up of residual mediastinal-hilar Ga-67 uptake after treatment for Hodgkin's and non-Hodgkin's lymphomas: what degree of Ga-67 uptake is significant?
Nikpoor N; Aliabadi P; Diaz L; Mannting F
Clin Nucl Med; 2000 Dec; 25(12):959-62. PubMed ID: 11129161
[TBL] [Abstract][Full Text] [Related]
26. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy.
Hoekstra OS; Ossenkoppele GJ; Golding R; van Lingen A; Visser GW; Teule GJ; Huijgens PC
J Nucl Med; 1993 Oct; 34(10):1706-10. PubMed ID: 8410287
[TBL] [Abstract][Full Text] [Related]
27. Aggressive non-Hodgkin lymphoma: early prediction of outcome with 67Ga scintigraphy.
Front D; Bar-Shalom R; Mor M; Haim N; Epelbaum R; Frenkel A; Gaitini D; Kolodny GM; Israel O
Radiology; 2000 Jan; 214(1):253-7. PubMed ID: 10644133
[TBL] [Abstract][Full Text] [Related]
28. Residual mass and negative gallium scintigraphy in treated lymphoma.
Israel O; Front D; Epelbaum R; Ben-Haim S; Jerushalmi J; Kleinhaus U; Even-Sapir E; Robinson E
J Nucl Med; 1990 Mar; 31(3):365-8. PubMed ID: 2308008
[TBL] [Abstract][Full Text] [Related]
29. Ga-67 SPECT before and after treatment of lymphoma.
Front D; Israel O; Epelbaum R; Ben Haim S; Sapir EE; Jerushalmi J; Kolodny GM; Robinson E
Radiology; 1990 May; 175(2):515-9. PubMed ID: 2183289
[TBL] [Abstract][Full Text] [Related]
30. The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients.
Front D; Israel O
Semin Nucl Med; 1995 Jan; 25(1):60-71. PubMed ID: 7716559
[TBL] [Abstract][Full Text] [Related]
31. [False-positive findings of 67-gallium scintigraphy in staging/restaging of malignant lymphoma].
Bihl H; Kimmig B
Rofo; 1987 Feb; 146(2):172-7. PubMed ID: 3029830
[TBL] [Abstract][Full Text] [Related]
32. Comparison of magnetic resonance imaging and (67)gallium scintigraphy in the evaluation of posttherapeutic residual mediastinal mass in the patients with Hodgkin's lymphoma.
Herman M; Paucek B; Raida L; Myslivecek M; Zapletalová J
Eur J Radiol; 2007 Dec; 64(3):432-8. PubMed ID: 17478069
[TBL] [Abstract][Full Text] [Related]
33. Hodgkin's disease: prognostic role of gallium scintigraphy after chemotherapy.
Brenot-Rossi I; Bouabdallah R; Di Stefano D; Bardou VJ; Stoppa AM; Camerlo J; Sauvan R; Gastaut JA; Pasquier J
Eur J Nucl Med; 2001 Oct; 28(10):1482-8. PubMed ID: 11685490
[TBL] [Abstract][Full Text] [Related]
34. When is hilar uptake of 67Ga-citrate indicative of residual disease after CHOP chemotherapy?
Frohlich DE; Chen JL; Neuberg D; Kehoe KM; Van den Abbeele AD
J Nucl Med; 2000 Feb; 41(2):269-74. PubMed ID: 10688110
[TBL] [Abstract][Full Text] [Related]
35. Gallium-67-citrate scintigraphy of high-grade T-cell non-Hodgkin's lymphoma.
Lipp RW; Sill H; Aigner R; Ranner G; Hoefler G; Passath A; Leb G
J Nucl Med; 1996 Sep; 37(9):1524-5. PubMed ID: 8790208
[TBL] [Abstract][Full Text] [Related]
36. Progress in medical imaging of lymphoma and Hodgkin's disease.
Bangerter M; Griesshammer M; Bergmann L
Curr Opin Oncol; 1999 Sep; 11(5):339-42. PubMed ID: 10505769
[TBL] [Abstract][Full Text] [Related]
37. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma.
Schiepers C; Filmont JE; Czernin J
Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S82-8. PubMed ID: 12719922
[TBL] [Abstract][Full Text] [Related]
38. [Use of Ga-67 SPECT in patients with malignant lymphoma after primary chemotherapy for further treatment planning: comparison with spiral CT].
Stroszczynski C; Amthauer H; Hosten N; Mapara M; Ricke J; Jochens R; Fischer-Funk E; Ludwig WD; Eichstädt H; Felix R
Rofo; 1997 Nov; 167(5):458-66. PubMed ID: 9440890
[TBL] [Abstract][Full Text] [Related]
39. Three cases demonstrating the role of gallium scanning in relapsing Hodgkin's disease and non-Hodgkin lymphoma.
Zollars LE; Nagel JS; Tumeh SS
J Nucl Med; 1987 Oct; 28(10):1611-5. PubMed ID: 3655913
[TBL] [Abstract][Full Text] [Related]
40. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma.
Hoh CK; Glaspy J; Rosen P; Dahlbom M; Lee SJ; Kunkel L; Hawkin RA; Maddahi J; Phelps ME
J Nucl Med; 1997 Mar; 38(3):343-8. PubMed ID: 9074514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
